2020 FDA Draft Guidance, "Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry"

Published on August 25, 2020
Biologics & Oligonucleotides
Drug Drug Interactions (DDI)
Regulatory Guidance
Regulatory Documents

In August 2020, the FDA released the draft guidance for industry to evaluate therapeutic proteins for drug-drug interaction (DDI) potential using a risk-based approach.

Download Publication

2020 FDA Draft Guidance, “Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry”